Please login to the form below

Not currently logged in
Email:
Password:

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

Biogen Idec building

Biogen has added another drug to its neuroscience pipeline, paying $75m upfront for rights to a Pfizer drug in development for cognitive impairment linked to schizophrenia.

The drug - PF-04958242 - is an AMPA receptor potentiator and glycine reuptake inhibitor heading for a phase IIb clinical trial in the second half of this year, and has already shown positive effects on cognition in early-stage studies.

Pfizer was also developing the candidate for age-related hearing loss but has abandoned that programme, and has since said it intends to exit neuroscience R&D altogether, cutting 300 jobs. This is thought to be the first asset sale since that decision.

According to Biogen, there are more than 20m people living with schizophrenia around the world and the majority of them live with some degree of cognitive impairment.

“When cognition is impaired, you lose the ability to make sense of the world,” said Michael Ehlers, Biogen’s head of R&D.

“Things we often take for granted in our daily lives, including processing information, planning and remembering, all become difficult or impossible,” he added, noting that cognition can be impaired in multiple neurological and neuropsychiatric diseases, not just schizophrenia.

Along with the $75m upfront payment, Biogen has agreed to pay Pfizer up to $515m in staged payments tied to development and commercial milestones, as well as low- to mid-teen royalties on sales.

Biogen is making a big R&D play in disease associated with cognitive impairment, and PF-04958242 will slot into its pipeline along with Alzheimer’s candidates aducanumab and E2609 in phase III, BAN2401 in phase II, and three other drugs in early-stage clinical trials.

The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201. Inbrija was resubmitted to the FDA in December after a first filing was turned down by the US regulator, while SYN-201 is currently in phase II development for the treatment of Parkinson’s disease-related dementia.

Article by
Phil Taylor

13th March 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics